LONA:NASDAQ
LeonaBio Inc
$4.76
arrow_downward
-1.65%(-0.080) 1D
$4.79
arrow_upward
+0.63% (+0.030)bedtimeAfter hours
Closed: Oct 26, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LONA...
Open
$4.80
High
$5.00
Low
$4.55
Mkt. cap
44.85M
Avg. vol.
350.41K
Volume
38.90K
52-wk high
$14.19
52-wk low
$2.21
EPS
-$19.72
Beta
2.11
Shares outstanding
9.42M
No. of employees
19
Open
$4.80
High
$5.00
Low
$4.55
Mkt. cap
44.85M
Avg. vol.
350.41K
Volume
38.90K
52-wk high
$14.19
52-wk low
$2.21
EPS
-$19.72
Beta
2.11
Shares outstanding
9.42M
No. of employees
19
News stories
From web sources and news partners
TradingView
·
33 minutes ago
Dow, S&P 500, Nasdaq Futures Climb As Tech Stocks Get A Boost From Anthropic IPO: SOFI, BB, PYPL, CLS In Focus
Yahoo Finance
·
6 hours ago
The 2 S&P 500 Stocks That Could Possibly Hold Up the Whole Index if the AI Trade Collapses
MarketWatch
·
6 hours ago
Why Lumentum’s stock led the S&P 500 higher on Monday
ChartMill
·
7 hours ago
S&P 500 Top Movers: Gainers and Losers in Today's US Session
Profile
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
About LeonaBio Inc
CEO-
Employees19
Founded2011
HeadquartersBothell, Washington, United States
SectorPharmaceutical industry
Websiteleonabio.com